2025年上半年，国新健康积极应对市场变化，持续优化业务结构，巩固"三医"基本盘，加速培育医疗健 康大数据创新业务，推动AI与医保、医疗、医药及健康服务的深度融合。聚焦医保基金综合管理服 务、医疗质量安全服务、药械监管与药企服务、健康服务创新，业务已覆盖全国29个省（自治区、直辖 市）的200多个地区。 报告期内，国新健康实现营业收入9553万元，业务结构进一步优化。数字医保领域，国新健康持续巩固 领先地位，与国家医保局合作实现多项突破。成功中标药品招采子系统及金额1066万元的医保飞行检查 等服务项目，承担国家追溯码应用研究课题，上半年在支付方式与基金监管市场占有率分别达40.5%和 17.4%，中标规模居行业首位。数字医药板块发展势头强劲，成功签约重庆"渝药安"、浙江药监局一体 化平台等项目，MDI项目实现新突破，DRO业务储备丰富。数字医疗板块不断加快AI转型，推出智能 审核2.0等产品，并积极布局疾控领域，推动"医院—疾控—卫健委"智慧服务生态建设。健康服务业务 稳步推进，优化慢病管理，多个慢病管理中心投入运营。 9月16日下午，国新健康保障服务集团股份有限公司（以下简称"国新健康"，股票代码：000 ...

Group 1 - The Ministry of Commerce and nine other departments have released policies to expand service consumption, focusing on easing market access in high-end medical and leisure vacation sectors to attract foreign and private investment [1] - The initiative aims to increase the supply of quality services and cultivate international markets in healthcare and exhibitions [1] - Analysts suggest that the expansion of the medical sector will create significant business opportunities in medical information technology and smart healthcare services [1] Group 2 - Companies such as Chuangshi Huikang and Langma Information are identified as relevant concepts in the A-share market related to the new policies [1]

9月16日，国新健康保障服务集团股份有限公司以电话会议形式召开业绩说明会，地点位于北京市东城 区沙滩后街22号院2号楼、3号楼。参与此次会议的有中国证券报、上海证券报等多家新闻媒体单位，以 及华泰证券、国联民生证券等超50家机构及个人投资者。公司党委副书记、董事、总经理袁洪泉，独立 董事孙娜，副总经理、总法律顾问、首席合规官周蔚，党委委员、总会计师王文长，董事会秘书刘新星 出席会议。 会上，总经理袁洪泉介绍了2025年半年度经营情况，并对未来工作进行展望；总会计师王文长汇报了 2025年半年度财务数据。随后的互动交流环节，投资者就公司AI应用、健康险业务、各板块业绩增长 等多方面进行提问，公司领导一一解答。 数字医药业务增长可期 公司数字医药业务上半年收入高增长，毛利率提升。因业务成本主要为人工成本且相对固定，收入增加 带动毛利率上升。业务从药械智慧监管向药企数字化服务拓展，市场空间广阔，有望持续增长。 AI应用广泛，助力业绩提升 投资者关注到公司上半年设立AI中心，推出相关模型和平台，询问AI应用及商业化情况、对业务的赋 能、对订单和业绩的影响，以及中长期战略规划。公司回应称，AI已在医保、医疗、医药等多领 ...

Group 1: Company Overview and Financial Performance - The company reported a significant increase in digital pharmaceutical services revenue, achieving an 81% growth in the first half of 2025, with gross margin rising to 6% [5] - The overall revenue of the company has seen a decline due to structural adjustments in health services and a decrease in digital medical business income [6] - The company aims to maintain revenue growth momentum and reduce operational losses through comprehensive reforms and efficiency improvements [6] Group 2: AI and Technology Integration - The company established an AI center and launched the "Tianshu·Three-Medical" model and "Lingxi" intelligent platform, enhancing AI applications across various business scenarios [3][4] - AI has been successfully implemented in multiple sectors, including medical insurance and healthcare, improving operational efficiency and service quality [3][4] - The company is focused on building a closed-loop AI capability in the three medical fields, leveraging data and algorithm breakthroughs [4] Group 3: Health Insurance and Market Trends - Recent national policies have provided clear directions for the health insurance industry, emphasizing innovation and multi-layered product systems [4] - The company is actively collaborating with insurance brokers and healthcare service providers to explore data-driven health insurance services [4] - The shift in insurance companies' focus from scale expansion to risk control and product innovation is shaping the industry landscape [4] Group 4: Digital Healthcare and Future Outlook - The company anticipates a stable foundation for its digital healthcare business, supported by ongoing reforms in payment methods and regulatory oversight [5] - There is a notable increase in demand for AI-enabled healthcare services, presenting new market opportunities [5] - The company plans to introduce new products such as hospital intelligent review 2.0 and outpatient payment services, leveraging its existing partnerships with over 800 hospitals [5] Group 5: Cost Management and Operational Efficiency - The company is implementing measures to enhance operational efficiency and optimize cost structures, focusing on reducing unnecessary expenditures [6][7] - Sales expense management is being prioritized, with strategies to improve sales team performance and resource allocation [7] - The company aims to achieve a balance between cost control and revenue generation through strategic planning and process optimization [7]

Core Viewpoint - The company is transitioning from a traditional IT product supplier to a cloud ecosystem enterprise that provides intelligent medical data services, driven by the need for efficiency in the healthcare industry [1][2]. Industry Transformation - The healthcare information industry is shifting from "system construction" to "data-driven value creation," focusing on long-term cloud services, data value extraction, and open ecosystem collaboration [2]. - The company has established a data-first advantage by forming strategic partnerships and accumulating extensive medical data, including over 1 million structured medical terms and relationships [2]. Product Development and Market Response - The company has developed the Hi-HIS management information system, which has seen a 200% increase in project deliveries in the first half of the year, with significant deployments in various regions [3]. - The MedCopilot intelligent assistant, built on the BsoftGPT model, significantly reduces documentation time and improves efficiency in clinical settings [4]. Technological Collaboration - The company is addressing challenges in computational power and high-quality medical data by collaborating with major tech firms and academic institutions to create a dynamic AI dataset [5][6]. - A joint laboratory with Zhejiang University aims to convert cutting-edge AI technologies into practical solutions for clinical problems, enhancing the synergy between research and application [6]. Future Aspirations - The company aims to deepen the integration of AI with clinical practices, enhance the value of medical data, and promote equitable healthcare through technology [7]. - The management emphasizes a structured talent development approach, ensuring a smooth transition of leadership and responsibilities across generations [7].

● 本报记者罗京 在张吕峥看来，医疗卫生行业具有高度的专业性，涉及大量的专业术语和复杂的医疗流程。要落地AI 应用需要积累大量的医疗变量需求，包括诊断、药品、治疗、护理等场景，以便构建能够理解和处理医 疗数据的AI模型。"公司基于BsoftGPT大模型服务平台开发的智能医生助手MedCopilot，已成为临床医 护的'智能副驾'。" 据介绍，MedCopilot围绕临床高频需求构建能力：在病历文书生成上，能自动抽取病程记录、检查报告 等信息，将出院小结撰写时间从30分钟压缩至5分钟；在医疗质控环节，实时提醒"诊断编码错误、手术 记录缺失"等问题，效率提升60%。"从数十家落地医院反馈看，医护人员终于能从繁琐文书中解脱，把 时间还给患者。"张吕峥说。 从早期推动医疗信息化联网，到如今向"智能云生态企业"转型，成立于1997年的创业慧康（300451）， 在医疗信息化行业已深耕近三十年，见证了行业从单机系统到网络化、从信息化到智能化的全过程。 "当前行业已进入全新的'效率竞争'阶段。"创业慧康董事长张吕峥近日接受中国证券报记者专访时表 示，公司始终以医疗业务痛点为导向，通过构建开放的云生态平台"慧康云3.0"，积 ...

● 本报记者 罗京 从早期推动医疗信息化联网，到如今向"智能云生态企业"转型，成立于1997年的创业慧康，在医疗信息 化行业已深耕近三十年，见证了行业从单机系统到网络化、从信息化到智能化的全过程。 "我们与全国数千家医疗机构共同成长，深刻理解医生、护士及管理者在临床一线的实际痛点。这种理 解使我们能够将数据转化为真正有价值的智能应用，比如公司自主研发的多态智联大型医疗机构（集 团）管理信息系统Hi-HIS，"张吕峥介绍。上半年，公司Hi-HIS系统的交付进度与市场认可度显著提 升，完成36个项目交付，同比增长200%，并在苏州、阿克苏等地实现大规模部署。 AI覆盖医疗信息化全业务链路 "当前行业已进入全新的'效率竞争'阶段。"创业慧康董事长张吕峥近日接受中国证券报记者专访时表 示，公司始终以医疗业务痛点为导向，通过构建开放的云生态平台"慧康云3.0"，积极布局AI和数据要 素，正从单纯的IT产品供应商转变为能够持续为医疗机构乃至医药、保险行业提供医疗数据智能服务的 云生态企业。 在张吕峥看来，医疗卫生行业具有高度的专业性，涉及大量的专业术语和复杂的医疗流程。要落地AI 应用需要积累大量的医疗变量需求，包括诊断 ...

Group 1: Company Overview - Neusoft has over 30 years of experience in the healthcare sector, being the leading provider of digital health solutions in China with the highest market share [3] - The company has developed a comprehensive industrial ecosystem covering medical insurance, smart healthcare, big data and AI in healthcare, medical equipment manufacturing, cloud hospitals, and health education [3] - Neusoft is the manufacturer of China's first CT scanner, with over 14,000 hospitals in more than 110 countries using its medical equipment, totaling over 50,000 installations [3] Group 2: Innovations and Solutions - Neusoft launched China's first photon-counting CT in August 2025, which is also the world's first 8cm wide photon-counting CT, marking a significant breakthrough in China's high-end medical equipment industry [3] - The integration of digital technology and healthcare is becoming a core driver of industry transformation, with data value realization in areas like elderly care and employment being crucial for high-quality national development [5] - Neusoft has introduced the "Tianyi" intelligent solution in the healthcare sector, successfully implemented in multiple hospitals, focusing on data value extraction from social security, medical insurance, and healthcare data [5] Group 3: Future Challenges and Goals - The core challenge for the healthcare system in the next five years is achieving more precise and balanced allocation of medical resources [6] - Neusoft aims to leverage AI and big data to enhance hospital operations, disease diagnosis, treatment, and health management, thereby addressing resource imbalance [6] - The company seeks to collaborate with partners globally to promote the digital and intelligent development of the healthcare industry, aiming to provide high-quality and efficient medical services [6]

Market Performance - On September 11, the medical information technology sector rose by 2.45% compared to the previous trading day, with Jiechuang Intelligent leading the gains [1] - The Shanghai Composite Index closed at 3875.31, up 1.65%, while the Shenzhen Component Index closed at 12979.89, up 3.36% [1] Stock Performance - Jiechuang Intelligent (301248) closed at 29.80, with a gain of 11.28% and a trading volume of 353,600 shares, amounting to a transaction value of 1.071 billion [1] - Other notable performers included: - Tuo Wei Information (002261) at 37.25, up 5.91% with a transaction value of 575.4 million [1] - Electric Science Digital (600850) at 28.65, up 5.88% with a transaction value of 79.56 million [1] - Hongjing Technology (301396) at 74.64, up 5.65% with a transaction value of 1.26 billion [1] Capital Flow - The medical information technology sector saw a net inflow of 728 million from institutional investors, while retail investors experienced a net outflow of 204 million [2][3] - The capital flow for key stocks included: - Tuo Wei Information with a net inflow of 389 million from institutional investors [3] - Yongyou Network (600588) with a net inflow of 170 million from institutional investors [3] - Runhe Software (300339) with a net inflow of 158 million from institutional investors [3]

Core Viewpoint - Philips (China) Investment Co., Ltd. reduced its stake in Chuangye Huikang by selling 560,500 shares, which represents 0.036292% of the total share capital after excluding shares in the repurchase account, bringing its ownership down from 10.036288% to 9.999996% [1] Summary by Relevant Sections - Shareholding Change - Philips (China) Investment Co., Ltd. sold 560,500 shares of Chuangye Huikang [1] - The reduction in shareholding is consistent with previously disclosed plans and has not been fully executed [1] - Impact on Company Control - The share reduction will not lead to a change in the control of the company [1] - The governance structure and ongoing operations of the company remain unaffected [1]